Box of Mounjaro & Wegovy

Mounjaro and Wegovy are powerful injectables used to manage obesity and type 2 diabetes, though they have different mechanisms and titration plans. The recent price increase in Mounjaro has left many people looking for alternative medications, with Wegovy at the top of many people’s lists.

If you are considering transitioning from Mounjaro to Wegovy, it’s important first to understand how to switch your weight loss medication safely, while maintaining consistency. 

This article walks you through the why, how, and what to anticipate when you switch medication from Mounjaro to Wegovy to help you make informed decisions.

What Is Mounjaro? 

Mounjaro is a prescription medication that belongs to the class of drugs called dual GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide) receptor agonists. The primary ingredient of this drug is Tirzepatide. [1]

Tirzepatide works by acting as a dual GLP-1 and GIP agonist. It slows gastric emptying, increases the feeling of fullness, reduces appetite, and maintains stable blood sugar levels. These effects contribute to weight loss. 

Clinical studies show that people on Mounjaro can lose a significant amount of weight, often more than with other GLP-1 medications. On average, participants in trials lost around 15 to 21% of their body weight over 72 weeks, depending on their dose. [2]

What Is Wegovy?

Wegovy is a GLP-1 agonist medication approved by the FDA for weight management. The primary ingredient of this drug is Semaglutide. [3]

Semaglutide works by mimicking a natural hormone called GLP-1, which helps regulate appetite and blood sugar. It slows digestion, lowers hunger, supports portion control, and reduces cravings. This helps promote steady, sustainable weight loss when combined with appropriate dietary and lifestyle changes.

Clinical research has shown that adults taking Wegovy lose around 15% of their body weight, or approximately 35 pounds, within 68 weeks of starting treatment. [4]

Can you switch from Mounjaro to Wegovy?

Yes, you can switch medication from Mounjaro to Wegovy if you meet the eligibility criteria for Wegovy (highly likely if you’re already on Mounjaro). You can contact our doctors and request that they review your case to determine your eligibility.

To be eligible for Wegovy treatment, you must:

  • Be 18 years or older.
  • Have a BMI that meets treatment thresholds (typically ≥30, or ≥27 with weight-related health conditions such as type 2 diabetes, high blood pressure, or sleep apnea).
  • Not have a history of allergy to Semaglutide.
  • Not have any medical conditions or be taking medications that could make Semaglutide unsafe for you.
  • Require additional help with weight management beyond diet and exercise alone.

Clinical Rationale for Switching from Mounjaro to Wegovy

Mounjaro and Wegovy both belong to the class of incretin mimetic medications but act via different pathways. Mounjaro is a dual agonist of GIP and GLP-1, while Wegovy targets GLP-1 receptors only. This difference can lead to varied efficacy and side effect profiles.

Research indicates Mounjaro may offer more substantial weight loss outcomes compared to Semaglutide, though individual responses vary. 

However, some patients experience more gastrointestinal side effects with Mounjaro compared to Wegovy. In such cases, switching to Wegovy may improve tolerability and enhance adherence to long-term treatment.

Most importantly, the manufacturer of Mounjaro, Eli Lilly, has announced an increase in the price of the medication for UK providers, effective from September. This means patients will need to pay more for this medication. So, if Mounjaro isn’t well-tolerated or becomes inaccessible due to cost, you can switch medication to Wegovy. Remember, any and all decisions of the sort should be made with the guidance of your professional clinical support system. 

Safe Transitioning Protocol When Switching from Mounjaro to Wegovy

Here are some critical points to remember when transitioning from Mounjaro to Wegovy:

Timing the Switch: Washout vs. Continuity

In most cases, no washout period is required to switch medication from Mounjaro to Wegovy. 

However, certain guidelines suggest taking a one-week pause before initiating Wegovy, particularly for patients prone to gastrointestinal side effects or those who experienced strong nausea or bloating due to Mounjaro. This short break is expected to give your digestive system a chance to reset before introducing new treatment.

A safe approach includes:

  • Administering your final dose of Mounjaro on your usual injection day.
  • Waiting seven days (or as advised by your doctor) before your first Wegovy injection.
  • Keeping the same weekly injection day for Wegovy to maintain a routine and reduce the risk of missed doses.
  • Starting Wegovy at the appropriate dose recommended by your healthcare provider based on your last Mounjaro dosage and your tolerance history.

This structured process will help you maintain your weight loss momentum while reducing the likelihood of adverse effects. 

Can You Switch from Mounjaro to Wegovy at a Higher Dose?

Yes. In many cases, you do not need to restart Wegovy from the very beginning if you are already established on Mounjaro. Your doctor may recommend a slightly higher starting dose of Wegovy than the standard beginner dose, depending on your current Mounjaro regimen.

However, the transition usually starts at a dose earlier in the usual titration schedule of Wegovy. This is done to reduce side effects while still continuing the progress you have made so far on Mounjaro.

Do You Get Withdrawal Symptoms When Switching?

No. There are no serious withdrawal symptoms associated with stopping Mounjaro or transitioning to Wegovy. However, you might notice a temporary increase in your appetite between your first and second Wegovy doses, but it’s nothing to be concerned about.

Also, some mild side effects may appear when your Wegovy dose increases. 

Some common Wegovy side effects include:

  • Nausea 
  • Vomiting
  • Diarrhea 
  • Constipation
  • Stomach pain 
  • Headaches
  • Tiredness

Mitigation Strategies To Avoid Side Effects

Here are some strategies to mitigate the side effects of Wegovy:

  • Titrate slowly and stay at a lower dose longer before escalating.
  • Take injections with food.
  • Stay hydrated and maintain adequate water intake.
  • Choose small, fiber-rich meals.
  • Maintain open communication with your provider and seek dosage changes as needed.

How To Maintain Weight Loss Momentum?

The most important aspect of transitioning to Wegovy is recognizing that this is not a reset but a continuation of your weight management journey.

Patients who successfully maintain momentum often:

  • Stick to their diet and exercise plans, making sure healthy habits are consistent regardless of the medication.
  • Track weight, energy levels, and side effects, noting any plateaus or sudden changes.
  • Seek the guidance of a healthcare provider, especially if weight loss slows significantly, as dose adjustments or extended titration steps may be needed.

Conclusion

Switching your weight loss medication from Mounjaro to Wegovy can be done safely, especially with a healthcare plan tailored to your past dosage, side effect profile, and lifestyle needs. It’s important to stay consistent with your routine, monitor the transition, and understand that small adjustments may be needed as your body adapts. With smart timing and proactive support from your doctor, you can continue your weight loss journey uninterrupted.


The Virtual Slimming Clinic is a clinically trusted provider of Wegovy and Mounjaro to prescribed patients, with our expert team capable of guiding you through the process of switching between them if necessary. Our blog also offers insights into other aspects of weight loss, ranging from diet to more medicinal pathways. Visit our website to learn more about how we can offer guidance in your weight loss journey. 

References:

  1. https://pubmed.ncbi.nlm.nih.gov/36751934/
  2. https://www.ncbi.nlm.nih.gov/books/NBK585056/
  3. https://pubmed.ncbi.nlm.nih.gov/34706925/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9272494/

Related articles